top of page

FDA's Device Center Is Authorizing More Novel Devices With Fewer People. Watch What's Shrinking.

Writer: Lexim AI
Lexim AI
Oct 29
4 min read

On October 22, CDRH Director Michelle Tarver closed out the AdvaMed MedTech Conference in Boston with a set of numbers that, read together, describe a regulator under real strain and adapting to it. CDRH authorized 151 novel medical devices in fiscal 2026, roughly triple the number it handled in 2009. It has now authorized 240 devices carrying predetermined change control plans. And it is rebuilding a review workforce that lost about 30% of its reviewers. Tarver also said the proposed MDUFA VI agreement is on track to reach Congress by January 2027.

Taken one at a time, each number is a headline. Taken together, they point at a question that matters more for planning than any single guidance document: when review capacity is tight, where does the work go? The early evidence suggests it is moving in two directions at once. FDA is publishing less new guidance, and it is authorizing more of a device's future before the device ever ships.

The guidance pipeline is getting smaller

On October 1, CDRH released its proposed guidance agenda for fiscal 2027, and the headline is the size of the list. It names 17 documents across all three tiers: 11 final guidances and three drafts planned for publication, plus three more under construction. That continues a steady decline in the number of documents CDRH is willing to put on its own to-do list: 29 in FY2025, 20 in FY2026, and now 17.

The agenda tracks what the center is actually delivering. According to the FDA Law Blog's analysis, CDRH has issued around 20 guidance documents so far in 2026, compared with roughly 40 per year on average between 2022 and 2024. That is half the output, at a moment when the technology CDRH regulates is moving faster than at any point in its history.

What survived the cut is telling. The FY2027 list leans heavily on software, AI, and cybersecurity: the final AI-enabled device software lifecycle guidance, a revised Policy for Device Software Functions (retitled, and one that many companies rely on when deciding whether their software is a device at all), updated postmarket cybersecurity recommendations, and a draft on generative AI conversational devices for mental disorders. Alongside those sit the cross-cutting items sponsors have waited on: a final PCCP guidance for all devices, quality management system information for certain premarket reviews, a refreshed Q-Submission program guidance, and small business qualification. Robotically assisted surgical devices also made the A-list; a draft was issued in September with comments due November 24, and FDA has scheduled a December 2-3 workshop on autonomous and remote teleoperation capabilities, which the draft does not cover.

Comments on the proposed lists are open through November 30.

What's growing: authorization of change in advance

The other side of the capacity story is the predetermined change control plan. A PCCP lets a manufacturer get a defined set of future modifications authorized inside the original marketing submission, then make those changes later without a new 510(k) or PMA supplement for each one.

Adoption is accelerating quickly. Medtech Insight reported that authorized PCCPs rose to 88 in fiscal 2025 from 27 the year before, and the 240 figure covers authorizations through September 30, 2026. On October 20, CDRH launched a dedicated PCCP web page that lists those 240 devices and adds hypothetical case examples for novel devices. Medtronic and its former diabetes unit MiniMed account for 41 of the entries, and Abbott, Thermo Fisher Scientific, and bioMérieux have each used the mechanism repeatedly. The all-devices PCCP guidance, meanwhile, is still on the FY2027 list as a final-guidance target.

An independent Booz Allen Hamilton review released earlier this month found that FDA has met its MDUFA V commitments to date, though 510(k) time to decision, a goal the agency shares with industry, keeps missing its target. That is a useful reminder that the strain is real even when headline performance goals hold.

A reading of the pattern, and its limits

FDA has not framed any of this as a strategy, and it would be a mistake to treat it as one. But the pattern is consistent enough to be worth planning around. A PCCP is, among other things, a way to review a change once instead of reviewing it every time it happens. A smaller guidance list means fewer new written interpretations of where the lines sit. Combined, they shift work toward the front of the process: more is expected to be specified, justified, and agreed in the original submission, and manufacturers carry more responsibility for governing themselves afterward.

If that reading is right, it has practical consequences. Questions that once got answered by waiting for a guidance document will increasingly be answered through Q-Submissions, case examples, and, as the next piece in this week's series covers, enforcement actions that show where FDA draws the line. And the cost of not using the pre-authorization tools goes up, because every change outside an authorized plan returns to the ordinary assessment of whether a new submission is needed.

What to do with this now

A few steps are worth taking before the end of the year. Review your near-termsubmission pipeline and identify which products have foreseeable post-clearance changes, such as model retraining, new sensor or hardware variants, or platform updates, that a PCCP could cover. Read FDA's new PCCP case examples and the authorized list for sponsors in your product area before drafting. Decide whether you have a view worth submitting on the FY2027 agenda by November 30, particularly if a software or AI guidance on the list affects your classification or change strategy. And if you are planning a robotics or autonomy program, note the November 24 comment date and the December workshop.

The broader signal is less about any one document than about who does the work and when. A device center that is doing more with fewer reviewers is going to reward sponsors who arrive with their change strategy already worked out.


Sources: Medtech Insight (Citeline), reporting on CDRH Director Michelle Tarver's remarks at the AdvaMed MedTech Conference, October 22, 2026; Medtech Insight, FDA's new PCCP pages and independent MDUFA V review, October 2026; FDA Law Blog, CDRH's FY 2027 Proposed Guidances, October 18, 2026; RAPS Regulatory Focus, FDA's device center releases guidance agenda for FY 2027; FDA CDRH News and Updates; Mondaq, FDA In Flux, October 2026 newsletter.

Comments


bottom of page